Skip to main content

Table 1 Details of the Mayo2 samples used in this study and genotype counts

From: Replication of EPHA1 and CD33 associations with late-onset Alzheimer's disease: a multi-centre case-control study

  Number of samples Mean Age (SD) % Female % ε4+
Series AD CON Total AD CON AD CON AD CON
Jacksonville 507 967 1,474 80.0 (6.7) 81.7 (7.6) 61.9 56.3 60.2 21.8
Rochester 317 1,638 1,955 85.8 (4.5) 80.3 (5.2) 62.1 54.6 42.3 22.4
Autopsy 312 102 414 87.4 (4.8) 86.0 (4.3) 67.6 52.0 61.2 14.7
Norway 346 555 901 80.2 (7.3) 75.3 (6.8) 69.9 59.8 63.0 24.1
Poland 483 188 671 76.7 (4.8) 73.0 (5.9) 66.3 76.6 56.4 19.0
ARUK 669 751 1,420 75.6 (8.2) 76.2 (7.3) 55.6 49.9 58.0 24.4
  1. The number of LOAD patients (AD) and controls (CON), mean age-at-diagnosis, percentage that are female and percentage that possess at least one copy of the APOE ε 4 allele are given for each individual series. Mean age is given as age at diagnosis/entry with the standard deviation (SD) from the mean in parentheses. None of the samples comprising the Jacksonville, Rochester and autopsy-confirmed Mayo Clinic or ARUK series (comprising Bristol, Leeds, Manchester, Nottingham, Oxford and Southampton), which were included in this follow-up study overlap with those used in the Naj et al. study and have not been included in any of the published LOAD GWAS. The Mayo2 dataset included in the Hollingworth et al. publication only included genotypes for ABCA7, MS4A6A and MA4A4E.